[Quadrivalent HPV 6/11/16/18 vaccine].
This randomized, double-blind study included 12,167 women who received three doses of quadrivalent HPV 6/11/16/18 vaccine or placebo (day 1, month 2, and month 6). The participants were followed for an average of 3 years. The vaccine prevented 98% of CIN2, CIN3 and adenocarcinoma in situ related to HPV 16 or HPV 18 among women not previously exposed to these types, and 44% among all women (i.e. both those with and without previous infection). The vaccine efficacy against all high-grade cervical lesions, independent of causal HPV type, was estimated to 17%.
Kjaer
Susanne Krüger
SK
Rigshospitalet, Juliane Marie Center, Kraeftens Bekaempelse, Institut for Epidemiologisk Kraeftforskning, Aalborg Sygehus. susanne@cancer.dk
Andersen
Erik Søgård
ES
Djursing
Henning
H
Hansen
Tom
T
Jørgensen
Jens Jørgen
JJ
Nilas
Lisbeth
L
Ottesen
Bent S
BS
Petersen
Lone Keld
LK
Thomsen
Steen Grove
SG
Toftager-Larsen
Kim
K